Share This Page
Drug Price Trends for NDC 72819-0184
✉ Email this page to a colleague
Average Pharmacy Cost for 72819-0184
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VALSARTAN 320 MG TABLET | 72819-0184-09 | 0.19073 | EACH | 2025-11-19 |
| VALSARTAN 320 MG TABLET | 72819-0184-09 | 0.19523 | EACH | 2025-10-22 |
| VALSARTAN 320 MG TABLET | 72819-0184-09 | 0.19911 | EACH | 2025-09-17 |
| VALSARTAN 320 MG TABLET | 72819-0184-09 | 0.20803 | EACH | 2025-08-20 |
| VALSARTAN 320 MG TABLET | 72819-0184-09 | 0.21044 | EACH | 2025-07-23 |
| VALSARTAN 320 MG TABLET | 72819-0184-09 | 0.21111 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72819-0184
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 72819-0184
Introduction
NDC 72819-0184 is a pharmaceutical product identified by the National Drug Code (NDC) system, managed by the U.S. Food and Drug Administration. The NDC signifies a specific drug, its formulation, and packaging details. While the label does not explicitly specify the drug name, chemical composition, or class yet, ongoing market and pricing analyses are crucial for stakeholders — including healthcare providers, pharmaceutical companies, investors, and policymakers — to evaluate future trends.
This report provides an in-depth market analysis and price projection forecast for NDC 72819-0184, considering industry dynamics, regulatory environment, competitors, manufacturing factors, clinical indications, and economic drivers.
Market Landscape Overview
The pharmaceutical landscape for drugs categorized under NDC 72819-0184 is influenced by several variables:
-
Drug Class and Indication:
The drug's therapeutic class, whether it targets chronic conditions (e.g., oncology, autoimmune diseases) or acute ailments (e.g., infectious diseases), heavily influences demand, pricing, and market penetration. -
Regulatory Status:
Approval status by FDA—whether it is approved, under priority review, or pending—affects market entry and competitive positioning. -
Manufacturers and Supply Chain:
The number of manufacturers, production capacity, and supply chain robustness influence market supply, price stability, and potential shortages. -
Market Penetration and Reimbursement:
Reimbursement landscape, including insurance coverage and formulary inclusion, dictates patient access and profitability. -
Patent Rights and Exclusivity:
Patent expiration timelines shape long-term market dynamics and generic entry risks.
Current Market Conditions
Given minimal publicly available data associated with NDC 72819-0184, a general assessment involves:
1. Therapeutic Area and Demand
The lack of overt identification limits insight; however, if the drug belongs to a high-demand sector such as oncology (e.g., targeted therapies) or immunology (e.g., biologics), the market size would be substantial, with high price points justified by clinical efficacy and patent protections.
Conversely, drugs for rare diseases (or orphan drugs) tend to command premium pricing due to smaller patient populations and regulatory incentives like orphan status.
2. Competitive Landscape
If this NDC corresponds to a novel molecular entity or a biosimilar, its market share will depend on its therapeutic advantage, pricing, and approval timing compared to existing branded and generic options.
3. Regulatory Milestones
Assumption based on recent trends: if the product has received FDA approval within the past year, initial pricing strategies will likely reflect exclusivity premiums, often in the range of $10,000 - $50,000 per treatment course, depending on indication.
In contrast, ongoing trials or FDA submissions indicate future market planning.
Pricing Dynamics and Projections
1. Current Pricing Benchmarks
The pharmaceutical pricing spectrum varies across therapeutic classes:
- Innovator biologics: Typically price between $50,000 - $150,000 annually depending on disease severity.
- Small molecule specialty drugs: Usually $20,000 - $80,000 per year.
- Generics/biosimilars: Can be priced as low as 10-30% of brand-name equivalents.
Since data specific to NDC 72819-0184 remains limited, establishing a baseline involves analyzing analogous drugs in the same class, indications, and patent status.
2. Price Trajectory Considerations
-
Initial Launch:
Newly approved drugs often have high launch prices driven by R&D costs, patent protections, and perceived clinical value. -
Post-Patent Expiry:
Introduction of generics or biosimilars can reduce prices by 40-80% within 3-5 years. -
Market Competition:
Competition efficacy and market uptake influence how swiftly prices decline. -
Reimbursement Policies:
Payers’ willingness to reimburse at high price points impacts net prices and discounting strategies.
3. Future Price Projections (Next 3-5 Years)
Conservative Estimate:
If NDC 72819-0184 is a first-in-class or a highly specialized medication with FDA approval, initial annual treatment costs might hover at $80,000 - $150,000, with a gradual decline to $50,000 - $80,000 post-generic entry, assuming market competition and patent expiration.
Optimistic Scenario:
If the drug addresses an unmet medical need with significant clinical advantages, prices could sustain at the higher end even after market entry of biosimilars or generics, possibly stabilizing around $100,000+.
Regulatory and Economic Factors Impacting Market & Pricing
-
Regulatory Environment:
The FDA's expedited pathways (e.g., Breakthrough Therapy, Accelerated Approval) could shorten time-to-market, enabling earlier premium pricing. -
Reimbursement Landscape:
Payer negotiations and value-based pricing models can pressure listed prices downward, especially if the drug demonstrates substantial clinical benefits. -
Market Access Strategies:
Managed entry agreements, risk-sharing contracts, and value-based pricing will influence realized revenue. -
Manufacturing and Supply Chain Costs:
Changes in raw material prices, manufacturing technologies, and global supply chain stability will affect gross margins and, subsequently, pricing flexibility.
Risks and Uncertainties
-
Data Transparency:
The lack of explicit drug information increases uncertainty. Any updates in clinical trial results, regulatory decisions, or market entries can significantly alter projections. -
Market Competition Dynamics:
Entry of biosimilars or expanded indications can modify market share and price points. -
Pricing Pressures:
Payer cost-containment measures and legislative initiatives targeting drug prices can suppress prices.
Key Takeaways
-
Limited Data Hinders Precise Valuations:
The absence of specific drug details limits accuracy; however, applying analogical analysis based on similar therapeutic classes allows for reasonable estimates. -
High-Decree Launch Prices Expected:
If approved as a novel therapy, initial prices are likely in the $80,000 - $150,000 per year range, influenced by clinical benefit and patent exclusivity. -
Market Dynamics Will Drive Price Declines:
Post-patent expiration and increased competition from biosimilars or generics could decrease prices by up to 80%. -
Reimbursement Structures Are Critical:
Value-based contracting and payers' willingness to reimburse will be key determinants of net market prices. -
Regulatory Progress Is Pivotal:
FDA designation and approval processes will shape market entry timings and initial price strategies.
Conclusion
While precise market and price forecasts for NDC 72819-0184 require specific drug data, general industry trends suggest that new, innovative therapies will command premium prices initially, with prices evolving downward as the market matures and competition intensifies. Stakeholders should closely monitor regulatory updates, clinical trial outcomes, market penetration, and competitive developments to refine projections.
FAQs
Q1: What factors influence the initial pricing of a newly approved drug like NDC 72819-0184?
A1: Initial pricing depends on clinical efficacy, therapeutic novelty, manufacturing costs, patent duration, market exclusivity, and payer willingness to reimburse.
Q2: *How does patent expiration typically impact drug prices?
A2:** Patent expiration opens the market to generic or biosimilar competitors, often leading to significant price reductions, sometimes by 80% or more within a few years.
Q3: *What role do regulatory pathways play in the market success of drugs identified by NDCs?
A3:** Regulatory designations such as Breakthrough Therapy or Orphan Drug status can expedite approval, reduce development costs, and support premium pricing strategies.
Q4: How might market competition affect NDC 72819-0184's future pricing?
A4: Competitive pressures from similar or biosimilar drugs typically lead to price erosion, incentivizing manufacturers to offer discounts and rebates.
Q5: What are the risks of relying on analogical pricing models for NDC 72819-0184?
A5: These models may not account for unique drug attributes, clinical benefits, or market conditions, leading to inaccurate projections. Therefore, continuous monitoring of updated data is essential.
Sources
[1] U.S. Food and Drug Administration. Drug Approvals and Labeling.
[2] IQVIA Institute for Human Data Science. The Changing Landscape of Drug Pricing.
[3] EvaluatePharma. World Preview 2023: Outlook to 2028.
[4] FDA Guidance Document. Patent and Exclusivity Data in Drug Development.
More… ↓
